<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425373</url>
  </required_header>
  <id_info>
    <org_study_id>CVAA489A1301</org_study_id>
    <nct_id>NCT00425373</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of fixed combination of
      valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone,
      and placebo in reducing blood pressure. The study will investigate the dose response
      relationship for the combinations, monotherapies, and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving MSDBP &lt; 90 mmHg or a =&gt; 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving MSDBP &lt; 90mmHg at the End of the Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving MSDBP &lt; 90 mm Hg and MSSBP &lt; 140 mm Hg at the End of the Study (Week 8)</measure>
    <time_frame>Baseline to end of study (Week 8)</time_frame>
    <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">1474</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Valsartan + amlodipine 40/2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan + amlodipine 40/5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan + amlodipine 80/2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan + amlodipine 80/5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan + amlodipine 40/2.5 mg</intervention_name>
    <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan + amlodipine 40/2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan + amlodipine 40/5 mg</intervention_name>
    <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan + amlodipine 40/5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan + amlodipine 80/2.5 mg</intervention_name>
    <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan + amlodipine 80/2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan + amlodipine 80/5 mg</intervention_name>
    <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan + amlodipine 80/5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 40 mg</intervention_name>
    <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80 mg</intervention_name>
    <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg</intervention_name>
    <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
    <arm_group_label>Amlodipine 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
    <arm_group_label>Amlodipine 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablet and 2 capsule placebos taken once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients with essential hypertension measured by electronic hemodynamometer. - -
             Patients must satisfy the following criteria.

               1. MSDBP &lt;110 mmHg and MSSBP &lt;180 mmHg at Visit 1

               2. MSDBP ≥ 90 mmHg and &lt; 110 mmHg and MSSBP &lt; 180 mmHg at Visit 2

               3. MSDBP ≥ 95 mmHg and &lt; 110 mmHg and MSSBP &lt; 180 mmHg at Visit 3

               4. The absolute difference in MSDBP between Visit 2 and 3 is ≤ 10 mmHg

          -  Male or female outpatients.

          -  Aged =&gt; 20 and =&lt; 80 years (at the time of signing informed consent).

          -  Patients who have written informed consent to participate in this study.

        Exclusion criteria

          -  Pregnant women, nursing (lactating) mothers, women suspected of being pregnant, or
             women who wish to be pregnant during the study, women of child-bearing potential.

          -  Patients with secondary hypertension or suspected of having secondary hypertension.

          -  Patients with a history of malignant hypertension.

          -  Patients with an inability to completely discontinue all prior antihypertensive
             medications safely for a period of 12 weeks as required by the protocol.

          -  Patients with or with a history of any of the following diseases or signs: Cardiac
             disease, renal disease, cerebrovascular disorder

          -  Patients with a clinically significant allergy (asthma on pharmacotherapy, multi-drug
             allergy, or drug-induced or food-induced anaphylactic reactions).

          -  Patients hypersensitive to AII receptor antagonists, calcium channel blockers or
             dihydropyridine derivatives.

          -  Known moderate or malignant retinopathy.

          -  Patients with or with a history of pancreatitis. Patients with pancreatic injury, or
             evidence of impaired pancreatic function/injury within 12 months of Visit 1.

          -  Patients with any surgical or medical condition which might significantly alter the
             absorption, distribution, metabolism, or excretion of any drug.

          -  Patients with volume depletion based on the investigator's or subinvestigator's
             clinical judgment using vital signs, skin turgor, moistness of mucous membrane and
             laboratory values.

          -  Patients who are found to have low Na and K (Na &lt;130 mEq/L, K &lt;3.3mEq/L) or high in
             these parameters (Na ≥ 152 mEq/L, K ≥ 5.2 mEq/L) by laboratory tests at Visit 1.

          -  Patients with type I diabetes mellitus on treatment with insulin, or patients with
             type II diabetes with poor glucose control defined as a glycosylated hemoglobin
             (HbA1c) &gt; 8.0% at Visit 1.

          -  Patients with or with a history of malignant tumors including leukemia and lymphoma,
             treated or untreated, within the past 5 years of Visit 1 whether or not there is
             evidence of local recurrence or metastases (except for localized basal cell carcinoma
             of the skin).

          -  Patients with any severe, life-threatening disease within the past 5 years. Patients
             with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus
             erythematosus.

          -  Any surgical or medical condition, which in the opinion of the investigator or
             subinvestigator, place the patient at higher risk from his/her participation in the
             study, or are likely to prevent the patient from complying with the requirement of the
             study or completing the trial period.

          -  Patients who have with or with a history of drug or alcohol abuse within the last 2
             years of Visit 1. Patients who have received other investigational product within 12
             weeks of Visit 1.

          -  Any chronic inflammatory condition needing chronic anti-inflammatory drug therapy.

          -  Persons directly involved in the execution of this study.

          -  Patients who are considered unlikely to comply with the requirements specified in the
             protocol by the investigator or subinvestigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Japan</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Tokyo</city>
        <zip>11111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2007</study_first_posted>
  <results_first_submitted>January 12, 2011</results_first_submitted>
  <results_first_submitted_qc>January 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2011</results_first_posted>
  <last_update_submitted>April 20, 2011</last_update_submitted>
  <last_update_submitted_qc>April 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Hypertension, Valsartan, Amlodipine, high blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valsartan + Amlodipine 40/2.5 mg</title>
          <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P2">
          <title>Valsartan + Amlodipine 40/5 mg</title>
          <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P3">
          <title>Valsartan + Amlodipine 80/2.5 mg</title>
          <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P4">
          <title>Valsartan + Amlodipine 80/5 mg</title>
          <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P5">
          <title>Valsartan 40 mg</title>
          <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P6">
          <title>Valsartan 80 mg</title>
          <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="P7">
          <title>Amlodipine 2.5 mg</title>
          <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
        </group>
        <group group_id="P8">
          <title>Amlodipine 5 mg</title>
          <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
        </group>
        <group group_id="P9">
          <title>Placebo</title>
          <description>4 tablet and 2 capsule placebos taken once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="162"/>
                <participants group_id="P5" count="169"/>
                <participants group_id="P6" count="163"/>
                <participants group_id="P7" count="161"/>
                <participants group_id="P8" count="161"/>
                <participants group_id="P9" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="159"/>
                <participants group_id="P6" count="154"/>
                <participants group_id="P7" count="154"/>
                <participants group_id="P8" count="151"/>
                <participants group_id="P9" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valsartan + Amlodipine 40/2.5 mg</title>
          <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B2">
          <title>Valsartan + Amlodipine 40/5 mg</title>
          <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B3">
          <title>Valsartan + Amlodipine 80/2.5 mg</title>
          <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B4">
          <title>Valsartan + Amlodipine 80/5 mg</title>
          <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B5">
          <title>Valsartan 40 mg</title>
          <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B6">
          <title>Valsartan 80 mg</title>
          <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B7">
          <title>Amlodipine 2.5 mg</title>
          <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
        </group>
        <group group_id="B8">
          <title>Amlodipine 5 mg</title>
          <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
        </group>
        <group group_id="B9">
          <title>Placebo</title>
          <description>4 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="162"/>
            <count group_id="B5" value="169"/>
            <count group_id="B6" value="163"/>
            <count group_id="B7" value="161"/>
            <count group_id="B8" value="161"/>
            <count group_id="B9" value="166"/>
            <count group_id="B10" value="1468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="10.34"/>
                    <measurement group_id="B2" value="52.8" spread="10.70"/>
                    <measurement group_id="B3" value="52.8" spread="10.76"/>
                    <measurement group_id="B4" value="54.1" spread="9.75"/>
                    <measurement group_id="B5" value="52.9" spread="10.08"/>
                    <measurement group_id="B6" value="52.6" spread="11.29"/>
                    <measurement group_id="B7" value="53.2" spread="10.83"/>
                    <measurement group_id="B8" value="54.4" spread="10.67"/>
                    <measurement group_id="B9" value="51.5" spread="10.58"/>
                    <measurement group_id="B10" value="53.1" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="49"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="55"/>
                    <measurement group_id="B10" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="131"/>
                    <measurement group_id="B6" value="114"/>
                    <measurement group_id="B7" value="112"/>
                    <measurement group_id="B8" value="121"/>
                    <measurement group_id="B9" value="111"/>
                    <measurement group_id="B10" value="1063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)</title>
        <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan + Amlodipine 40/2.5 mg</title>
            <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Valsartan + Amlodipine 40/5 mg</title>
            <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O3">
            <title>Valsartan + Amlodipine 80/2.5 mg</title>
            <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O4">
            <title>Valsartan + Amlodipine 80/5 mg</title>
            <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 40 mg</title>
            <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 80 mg</title>
            <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O7">
            <title>Amlodipine 2.5 mg</title>
            <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O8">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>4 tablet and 2 capsule placebos taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)</title>
          <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
          <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
                <count group_id="O8" value="161"/>
                <count group_id="O9" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="0.62"/>
                    <measurement group_id="O2" value="-16.5" spread="0.60"/>
                    <measurement group_id="O3" value="-12.6" spread="0.62"/>
                    <measurement group_id="O4" value="-17.0" spread="0.61"/>
                    <measurement group_id="O5" value="-8.5" spread="0.60"/>
                    <measurement group_id="O6" value="-8.8" spread="0.61"/>
                    <measurement group_id="O7" value="-10.3" spread="0.61"/>
                    <measurement group_id="O8" value="-13.4" spread="0.61"/>
                    <measurement group_id="O9" value="-4.8" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)</title>
        <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan + Amlodipine 40/2.5 mg</title>
            <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Valsartan + Amlodipine 40/5 mg</title>
            <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O3">
            <title>Valsartan + Amlodipine 80/2.5 mg</title>
            <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O4">
            <title>Valsartan + Amlodipine 80/5 mg</title>
            <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 40 mg</title>
            <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 80 mg</title>
            <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O7">
            <title>Amlodipine 2.5 mg</title>
            <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O8">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>4 tablet and 2 capsule placebos taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)</title>
          <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
          <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
                <count group_id="O8" value="161"/>
                <count group_id="O9" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="0.88"/>
                    <measurement group_id="O2" value="-22.0" spread="0.86"/>
                    <measurement group_id="O3" value="-16.9" spread="0.88"/>
                    <measurement group_id="O4" value="-22.9" spread="0.87"/>
                    <measurement group_id="O5" value="-9.3" spread="0.85"/>
                    <measurement group_id="O6" value="-9.5" spread="0.87"/>
                    <measurement group_id="O7" value="-13.6" spread="0.87"/>
                    <measurement group_id="O8" value="-16.6" spread="0.87"/>
                    <measurement group_id="O9" value="-4.4" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving MSDBP &lt; 90 mmHg or a =&gt; 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)</title>
        <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan + Amlodipine 40/2.5 mg</title>
            <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Valsartan + Amlodipine 40/5 mg</title>
            <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O3">
            <title>Valsartan + Amlodipine 80/2.5 mg</title>
            <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O4">
            <title>Valsartan + Amlodipine 80/5 mg</title>
            <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 40 mg</title>
            <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 80 mg</title>
            <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O7">
            <title>Amlodipine 2.5 mg</title>
            <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O8">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>4 tablet and 2 capsule placebos taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving MSDBP &lt; 90 mmHg or a =&gt; 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)</title>
          <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
          <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
                <count group_id="O8" value="161"/>
                <count group_id="O9" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="88.0"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="86.4"/>
                    <measurement group_id="O5" value="52.1"/>
                    <measurement group_id="O6" value="47.9"/>
                    <measurement group_id="O7" value="62.1"/>
                    <measurement group_id="O8" value="74.5"/>
                    <measurement group_id="O9" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving MSDBP &lt; 90mmHg at the End of the Study (Week 8)</title>
        <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan + Amlodipine 40/2.5 mg</title>
            <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Valsartan + Amlodipine 40/5 mg</title>
            <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O3">
            <title>Valsartan + Amlodipine 80/2.5 mg</title>
            <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O4">
            <title>Valsartan + Amlodipine 80/5 mg</title>
            <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 40 mg</title>
            <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 80 mg</title>
            <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O7">
            <title>Amlodipine 2.5 mg</title>
            <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O8">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>4 tablet and 2 capsule placebos taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving MSDBP &lt; 90mmHg at the End of the Study (Week 8)</title>
          <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
          <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
                <count group_id="O8" value="161"/>
                <count group_id="O9" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3"/>
                    <measurement group_id="O2" value="82.6"/>
                    <measurement group_id="O3" value="72.5"/>
                    <measurement group_id="O4" value="80.9"/>
                    <measurement group_id="O5" value="46.2"/>
                    <measurement group_id="O6" value="41.1"/>
                    <measurement group_id="O7" value="55.3"/>
                    <measurement group_id="O8" value="67.1"/>
                    <measurement group_id="O9" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving MSDBP &lt; 90 mm Hg and MSSBP &lt; 140 mm Hg at the End of the Study (Week 8)</title>
        <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
        <time_frame>Baseline to end of study (Week 8)</time_frame>
        <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan + Amlodipine 40/2.5 mg</title>
            <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Valsartan + Amlodipine 40/5 mg</title>
            <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O3">
            <title>Valsartan + Amlodipine 80/2.5 mg</title>
            <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O4">
            <title>Valsartan + Amlodipine 80/5 mg</title>
            <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O5">
            <title>Valsartan 40 mg</title>
            <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O6">
            <title>Valsartan 80 mg</title>
            <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
          </group>
          <group group_id="O7">
            <title>Amlodipine 2.5 mg</title>
            <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O8">
            <title>Amlodipine 5 mg</title>
            <description>Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>4 tablet and 2 capsule placebos taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving MSDBP &lt; 90 mm Hg and MSSBP &lt; 140 mm Hg at the End of the Study (Week 8)</title>
          <description>At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.</description>
          <population>Intent-to-treat (ITT): All randomized patients who had a baseline and at least one post-baseline assessment of the variable analyzed. Baseline is the Week 0 value and end of study is the value at Week 8 or the last observation carried forward (LOCF) value.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="162"/>
                <count group_id="O5" value="169"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
                <count group_id="O8" value="161"/>
                <count group_id="O9" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="75.4"/>
                    <measurement group_id="O3" value="59.4"/>
                    <measurement group_id="O4" value="72.2"/>
                    <measurement group_id="O5" value="33.1"/>
                    <measurement group_id="O6" value="30.1"/>
                    <measurement group_id="O7" value="41.0"/>
                    <measurement group_id="O8" value="57.1"/>
                    <measurement group_id="O9" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>4 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E2">
          <title>Valsartan 40 mg</title>
          <description>Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E3">
          <title>Valsartan 80 mg</title>
          <description>Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E4">
          <title>Amlodipine 2.5 mg</title>
          <description>Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily</description>
        </group>
        <group group_id="E5">
          <title>Valsartan + Amlodipine 40/2.5 mg</title>
          <description>Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E6">
          <title>Valsartan + Amlodipine 80/2.5 mg</title>
          <description>Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E7">
          <title>Amlodipine 5 mg</title>
          <description>Amlodipine 2.5 mg 2 capsules plus 4 tablet placebos taken once daily</description>
        </group>
        <group group_id="E8">
          <title>Valsartan + Amlodipine 40/5 mg</title>
          <description>Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
        <group group_id="E9">
          <title>Valsartan + Amlodipine 80/5 mg</title>
          <description>Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="167"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

